Vraylar (cariprazine) is not FDA-approved to treat anxiety disorders. It is approved for schizophrenia, acute manic or mixed episodes in bipolar I disorder, and as an add-on therapy for major depressive disorder. However, there is growing evidence that Vraylar can reduce anxiety symptoms, particularly when they occur alongside depression, and some doctors prescribe it off-label with that goal in mind.
What Vraylar Is Approved For
Vraylar received its first FDA approval in 2015 for schizophrenia and acute manic or mixed episodes of bipolar I disorder. In 2022, it gained an additional approval as an adjunctive (add-on) therapy for major depressive disorder in adults who haven’t responded well enough to an antidepressant alone. None of these approvals cover generalized anxiety disorder, social anxiety disorder, panic disorder, or any other standalone anxiety diagnosis.
That said, atypical antipsychotics like Vraylar are prescribed off-label for nonpsychotic conditions, including anxiety, more often than many people realize. One analysis found that atypical antipsychotics were prescribed to more than 70% of patients with nonpsychotic conditions such as anxiety disorders. Off-label use is legal and common in psychiatry, but it means the drug hasn’t gone through the full approval process specifically for that condition.
Evidence That Vraylar Reduces Anxiety Symptoms
The strongest human data on Vraylar and anxiety comes from a post hoc analysis of a phase 3 clinical trial involving 751 adults with major depressive disorder who hadn’t improved enough on antidepressants. Researchers looked at whether adding Vraylar at 1.5 mg or 3.0 mg per day improved anxiety symptoms alongside depression. It did. At the lower dose, patients showed statistically significant reductions in anxiety scores compared to placebo, both on a general anxiety scale and on a specific measure of anxious depression. The 3.0 mg dose also reduced anxiety, though the effect was smaller.
Importantly, these benefits appeared regardless of whether patients started the trial with mild or moderate anxiety. In the subgroup with elevated baseline anxiety (sometimes called “anxious depression”), the 1.5 mg dose produced notably larger improvements in overall depression scores as well, suggesting that Vraylar may be especially useful when anxiety and depression overlap.
There is one critical caveat: this was a post hoc analysis, meaning the researchers went back and looked at anxiety outcomes after the trial was already designed to measure depression. It’s suggestive, not definitive. No large randomized trial has been designed from the start to test Vraylar specifically for an anxiety disorder.
How Vraylar Might Work on Anxiety
Vraylar has a unique pharmacological profile that sets it apart from other atypical antipsychotics. It acts as a partial agonist at dopamine D2 and D3 receptors, meaning it can either boost or dampen dopamine signaling depending on what the brain needs at the time. What makes it unusual is its strong preference for D3 receptors, binding to them about six to eight times more readily than D2 receptors. Among all available antipsychotics, Vraylar has the highest D3 receptor affinity.
D3 receptors are concentrated in a part of the brain’s reward and motivation circuitry that plays a role in both depression and anxiety. In animal studies, Vraylar produced anti-anxiety-like effects in behavioral tests and also countered anhedonia, the inability to feel pleasure that characterizes many mood disorders. When researchers repeated those experiments in mice genetically engineered to lack D3 receptors, the benefits disappeared, confirming that D3 activity drives much of the drug’s effect on mood. Vraylar also appears to increase D3 receptor levels in key brain regions over time, a change that has been proposed as a shared mechanism among different types of antidepressant treatments.
Side Effects to Be Aware Of
Vraylar’s side effect profile matters especially if you’re considering it for anxiety, because one of its most common side effects, akathisia, can feel a lot like anxiety itself. Akathisia is an inner restlessness or an uncomfortable urge to move. In the depression trial, akathisia occurred in about 5% of patients on the 1.5 mg dose and nearly 8% on the 3.0 mg dose, compared to less than 1% on placebo. Nausea was the other frequently reported issue, affecting roughly 6 to 8% of patients on Vraylar versus about 2% on placebo.
If you’re taking Vraylar and notice that your restlessness or anxiety seems worse rather than better, akathisia is worth discussing with your prescriber. The distinction between “my anxiety is acting up” and “this medication is making me feel agitated” can be hard to sort out on your own, but it changes the treatment plan significantly.
Why a Doctor Might Prescribe It for Anxiety
The most common scenario where Vraylar enters the picture for anxiety is when someone has depression with significant anxiety symptoms and hasn’t responded well to a standard antidepressant like an SSRI or SNRI. In that situation, Vraylar is being used within its approved indication for treatment-resistant depression, and the anxiety benefit comes along with it. This is the scenario supported by the clinical trial data described above.
Less commonly, a psychiatrist might prescribe Vraylar off-label for anxiety that exists without a primary depression diagnosis. This would be based on clinical judgment and the drug’s pharmacology rather than on robust trial data. If your doctor suggests this route, it’s reasonable to ask what evidence they’re drawing on and what alternatives have already been tried.
For straightforward anxiety disorders without depression, first-line treatments remain SSRIs, SNRIs, buspirone, and certain forms of psychotherapy like cognitive behavioral therapy. Vraylar is not a replacement for those options. It occupies a different place in the treatment landscape: a later-stage option when standard approaches haven’t worked well enough, particularly when anxiety and depression are intertwined.